Foghorn Therapeutics Inc. (FHTX:NASDAQ) closed at $1.87 on November 6, 2026, down 1.84% on the day. The stock trades 75.4% below its 52-week high of $7.61 and 4.5% above its 52-week low of $1.79. Over the past year, it lost 57.1%. Foghorn Therapeutics Inc. is part of the Health Care sector.
In 252 trading sessions since November 6, 2025, FHTX closed higher on 113 days (45%). Its best day was January 12, 2026 (+23.64%) and its worst was October 2, 2026 (-30.82%). The stock moved 10% or more in a single session 10 times.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Find more stocks like FHTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.